Daan Gene Co Ltd Class A 002030
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥5.54
- Day Range
- ¥5.60–5.95
- 52-Week Range
- ¥4.71–11.00
- Bid/Ask
- ¥5.83 / ¥5.84
- Market Cap
- ¥8.20 Bil
- Volume/Avg
- 36.6 Mil / 29.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- 11.56
- Price/Sales
- 7.94
- Dividend Yield (Trailing)
- 0.26%
- Dividend Yield (Forward)
- 0.26%
- Total Yield
- 0.26%
Company Profile
Daan Gene Co Ltd is a high-tech enterprise-oriented in molecular diagnostic techniques. It is primarily committed to research and development, production, and service of in-vitro diagnostic products, including qPCR, Sequeacing, TRF, ELISA, and Liquid-Based Cytology diagnostic kits and equipment. Geographically, tahe group operates in China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 1,968
- Website
- https://www.daangene.com
Comparables
Valuation
|
Metric
|
002030
|
688468
|
688253
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.56 | 18.73 | 19.62 |
Price/Book Value | 0.97 | 1.82 | 2.70 |
Price/Sales | 7.94 | 5.48 | 8.00 |
Price/Cash Flow | 13.72 | 12.83 | 15.34 |
Price/Earnings
002030
688468
688253
Financial Strength
|
Metric
|
002030
|
688468
|
688253
|
|---|---|---|---|
Quick Ratio | 2.15 | 4.71 | 15.40 |
Current Ratio | 4.15 | 5.48 | 15.84 |
Interest Coverage | −78.04 | 111.54 | 2,238.82 |
Quick Ratio
002030
688468
688253
Profitability
|
Metric
|
002030
|
688468
|
688253
|
|---|---|---|---|
Return on Assets (Normalized) | −5.89% | 7.46% | 12.17% |
Return on Equity (Normalized) | −7.30% | 9.59% | 13.13% |
Return on Invested Capital (Normalized) | −7.42% | 7.98% | 12.68% |
Return on Assets
002030
688468
688253
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xrsbzclsd | Xzf | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wktywxgd | Mbsnbv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hmzhbgs | Vkdssq | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qnbsdxsjl | Qctrsn | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Hrwcdtq | Ndkj | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Crmlnmtp | Qmvb | $28.1 Bil | |||
| Moderna Inc
MRNA
| Mmzpjhbzt | Yhww | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bgcdmgyn | Cgpml | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zlbksqkt | Kbkltg | $13.4 Bil | |||
| Incyte Corp
INCY
| Mwqdztlz | Qcknyl | $12.7 Bil |
United States